Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
Trinity Biotech plc (Nasdaq: TRIB) reported Q1 2020 revenues of $21.2 million, down from $22.0 million in Q1 2019. Point-of-Care revenue increased by 4.4% to $3.3 million, while Clinical Laboratory revenue fell 5.3% to $17.8 million. Gross profit was $9.3 million with a margin of 43.8%. Operating profit rose to $1.7 million, and basic EPS increased to 1.7 cents. The company anticipates Q2 revenues of $13-15 million due to impacts from Covid-19, though it is in the validation phase for a Covid-19 IgG test.
Trinity Biotech (Nasdaq: TRIB) will announce its Q1 2020 financial results on May 27, 2020. A conference call is scheduled for the same day at 11:00 AM ET (4:00 PM BST) to discuss the results. Interested parties can join via a designated dial-in number or access a simultaneous webcast. The replay of the call will be available until June 3, 2020. The company specializes in diagnostic products for both point-of-care and clinical laboratory markets, with global operations in over 75 countries.